CA Patent

CA3166973C — DOCETAXEL FORMULATIONS

Assigned to Zhuhai Beihai Biotech Co Ltd · Expires 2025-03-18 · 1y expired

What this patent protects

This document relates to a pharmaceutical formulation of docetaxel, or a pharmaceutically acceptable salt thereof, with two compositions that are mixed prior to being infused or administered to patients, that comprises: (a) a first liquid composition comprising docetaxel, or a ph…

USPTO Abstract

This document relates to a pharmaceutical formulation of docetaxel, or a pharmaceutically acceptable salt thereof, with two compositions that are mixed prior to being infused or administered to patients, that comprises: (a) a first liquid composition comprising docetaxel, or a pharmaceutically acceptable salt thereof, and ethanol, and (b) a second aqueous composition comprising human serum albumin and a parenterally acceptable vehicle, and wherein the said pharmaceutical formulation does not contain Polysorbate 80.

Drugs covered by this patent

Patent Metadata

Patent number
CA3166973C
Jurisdiction
CA
Classification
—
Expires
2025-03-18
Drug substance claim
No
Drug product claim
No
Assignee
Zhuhai Beihai Biotech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.